7-Hydroxystaurosporine

Generic Name: 7-Hydroxystaurosporine

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₂₆N_₄O_₄

CAS Number: 112953-11-4

Unique Ingredient Identifier: 7BU5H4V94A

Clinical Trials

7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Acute Promyelocytic Leukemia (M3)
Adult Erythroleukemia (M6a)
Adult Pure Erythroid Leukemia (M6b)
Blastic Phase Chronic Myelogenous Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
Secondary Acute Myeloid Leukemia

Interventions: Drug: 7-hydroxystaurosporine
Drug: perifosine
Other: pharmacological study

First Posted Date: 2006-03-13

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00301938

Locations: 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Small Cell Lung Cancer
Extensive Stage Small Cell Lung Cancer

Interventions: Drug: topotecan hydrochloride
Drug: 7-hydroxystaurosporine

First Posted Date: 2004-12-09

Last Posted Date: 2018-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00098956

Locations: 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada

Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Myelodysplastic Syndromes
Leukemia

Interventions: Drug: 7-hydroxystaurosporine (UCN-01)
Drug: Cytarabine (Ara-C)

First Posted Date: 2004-07-26

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00004263

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States

UCN-01 in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-05-21

Last Posted Date: 2010-08-09

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT00003289

Locations: 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States

UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-11-06

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00072267

Locations: 🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

and more 1 locations

A Phase II Study of UCN-01 in Metastatic Melanoma

Phase 2

Terminated

Conditions: Stage IV Melanoma
Recurrent Melanoma

Interventions: Drug: 7-hydroxystaurosporine
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-11-06

Last Posted Date: 2015-03-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT00072189

Locations: 🇺🇸
UC Davis Cancer Center, Sacramento, California, United States

UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-05-30

Last Posted Date: 2010-01-15

Lead Sponsor: City of Hope Medical Center

Registration Number: NCT00006464

Locations: 🇺🇸
City of Hope Medical Group, Pasadena, California, United States
🇺🇸
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

and more 1 locations

Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-05-08

Last Posted Date: 2013-06-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00004059

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer

Phase 2

Conditions: Kidney Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2014-01-06

Lead Sponsor: University of California, San Francisco

Registration Number: NCT00030888

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States

UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: 7-hydroxystaurosporine
Drug: gemcitabine hydrochloride
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00039403

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy